The firm is developing a multipanel test and an antibiotic resistance panel to augment its recently CE marked chlamydia and gonorrhea assay.
The firm said that its point-of-care test delivers laboratory-quality results in about 30 minutes and could be used in the home and other settings.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
The agreements involve the commercialization of the NeuMoDx 288 and 96 platforms for fully integrated, sample-to-answer, PCR-based molecular diagnostic testing.
The Ann Arbor, Michigan-based firm will compete with a few well-established players offering systems that can run in vitro diagnostic tests as well as lab-developed tests.
The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
In PLOS this week: genetic diversity of Trypanosoma cruzi, sequencing analysis of Chlamydia from turtles, and more.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.